Salarius Pharmaceuticals, Inc. (SLRX)
Stock Price:
$1.18 USD
0.04 (3.07%)
Updated Aug 10, 2020 10:57 AM EDT - Market open
Key Info
| Market Cap |
17.20M |
| Revenue (ttm) |
3.94M |
| Net Income (ttm) |
-7.98M |
| Shares Out |
14.64M |
| EPS (ttm) |
-1.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$1.18 |
| Previous Close |
$1.14 |
| Change ($) |
0.04 |
| Change (%) |
3.07% |
| Day's Open |
1.16 |
| Day's Range |
1.16 - 1.19 |
| Day's Volume |
63,703 |
| 52-Week Range |
0.56 - 13.50 |
More Stats
| Market Cap |
17.20M |
| Enterprise Value |
7.81M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
14.64M |
| Float |
10.96M |
| EPS (basic) |
-3.39 |
| EPS (diluted) |
-1.48 |
| FCF / Share |
-1.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
984,161 |
| Short Ratio |
2.06 |
| Short % of Float |
6.56% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.36 |
| PB Ratio |
0.97 |
| Revenue |
3.94M |
| Operating Income |
-9.59M |
| Net Income |
-7.98M |
| Free Cash Flow |
-12.63M |
| Net Cash |
9.39M |
| Net Cash / Share |
0.64 |
| Gross Margin |
-14.05% |
| Operating Margin |
-243.21% |
| Profit Margin |
-248.50% |
| FCF Margin |
-320.36% |
| ROA |
-35.42% |
| ROE |
-76.53% |
| ROIC |
696.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.40*
(274.47% upside)
Low
3.80
Current: $1.18
High
5.00
Target: 4.40
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 3.47 | 1.95 | 1.85 | 1.01 | - |
| Revenue Growth | 77.57% | 5.37% | 83.24% | - | - |
| Gross Profit | 3.47 | 1.95 | 1.85 | 0.35 | - |
| Operating Income | -8.27 | -1.68 | -1.75 | -39.89 | -29.21 |
| Net Income | -6.94 | -1.67 | -1.75 | -39.49 | -29.14 |
| Shares Outstanding | 3.27 | 1.54 | 1.15 | 0.65 | 0.56 |
| Earnings Per Share | -2.12 | -1.16 | -1.60 | -60.75 | -52.00 |
| Operating Cash Flow | -11.58 | 4.18 | -1.46 | -32.05 | -20.75 |
| Capital Expenditures | - | - | - | -0.55 | -0.27 |
| Free Cash Flow | -11.58 | 4.18 | -1.46 | -32.61 | -21.01 |
| Cash & Equivalents | 3.74 | 6.13 | 0.52 | 61.20 | 91.47 |
| Total Debt | 0.50 | - | - | - | - |
| Net Cash / Debt | 3.24 | 6.13 | 0.52 | 61.20 | 91.47 |
| Assets | 13.89 | 6.61 | 0.69 | 63.21 | 95.07 |
| Liabilities | 3.31 | 7.88 | 1.72 | 3.90 | 2.88 |
| Book Value | 10.58 | -1.27 | -2.90 | 59.32 | 92.19 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Salarius Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
7 |
| CEO |
David J. Arthur |
Stock Information
| Ticker Symbol |
SLRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SLRX |
Description
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.